Efficacy and safety of pumecitinib 3% gel in treating mild-to-moderate atopic dermatitis: a multicentre randomized double-blind parallel placebo-controlled phase IIb clinical trial
British Journal of Dermatology · 2026
DOI: 10.1093/bjd/ljaf363 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2026. Verfasst von Li Zhang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dermatologic Agents. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: research and development.
Abstract (Originalsprache)
Background
We conducted a phase IIb clinical trial of pumecitinib 3% gel (PG-011), a novel selective Janus kinase (JAK)1/2 inhibitor, applied topically to treat mild-to-moderate atopic dermatitis (AD).
Objectives
To assess pumecitinib 3% gel for its efficacy and safety in treating adult patients with mild-to-moderate AD, and to determine the optimal treatment regimen.
Methods
In this study, 139 participants with mild-to-moderate AD were randomized 1 : 1 : 1 to pumecitinib 3% gel twice daily (n = 47), pumecitinib 3% gel once daily (n = 46) and placebo (n = 46) for 8 weeks of treatment. Percentage change in Eczema Area and Severity Index (EASI) score from baseline to week 8 was the primary efficacy endpoint. The percentage of participants with an Investigator’s Global Assessment score of 0 or 1 (≥ 2-point improvement from baseline) at week 8, the proportion of participants attaining ≥ 50% improvement in EASI (EASI 50), ≥ 75% improvement in EASI (EASI 75) and ≥ 90% improvement in EASI (EASI 90) at week 8, and improvement in quality of life were also evaluated. Safety, local tolerability and some pharmacokinetics were monitored.
Results
At week 8, the percentage change from baseline in EASI score in the pumecitinib 3% gel twice daily, pumecitinib 3% gel once daily and placebo groups was –83.6%, –44.0% and –22.0%, respectively. Both pumecitinib treatment regimens showed a significantly greater effect compared with placebo (P < 0.006) and the pumecitinib 3% gel twice-daily regimen had a greater effect than once-daily treatment (P < 0.001). Other efficacy endpoints were also improved in participants in the pumecitinib groups vs. those in the placebo group, and pumecitinib 3% gel twice daily consistently exhibited better efficacy than the once-daily treatment. With regard to safety, the rate of adverse events in the pumecitinib and placebo groups was 48% and 48%, respectively. Safety profiles were generally similar between the pumecitinib and placebo groups, and treatment was well tolerated. Mean plasma drug concentrations were low (range 38–104 pg mL–1) over the 8-week treatment period.
Conclusions
Pumecitinib 3% gel showed good efficacy and safety profiles in the treatment of adults with mild-to-moderate AD. The pumecitinib 3% twice-daily treatment regimen showed greater efficacy than the once-daily regimen in treating mild-to-moderate AD. Pumecitinib 3% gel was well tolerated and generated low systemic drug exposure when used topically. It may be a new choice of topical JAK inhibitor to treat mild-to-moderate AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The First Hospital of China Medical University, Shenyang, China.
- Key Laboratory of Immunodermatology, Ministry of Education, and National Health Commission; National Joint Engineering Research Center for Theranostics of Immunological Skin Diseases, Shenyang, China.
- Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
- Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China.
- Department of Dermatology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
- Department of Dermatology, Affiliated Hangzhou First People's Hospital, School of Medicine, West Lake University, Hangzhou, China.
ORCID-Profile: Xinghua Gao
Förderung
- research and development
Zitieren
APA
Zhang, L., Wang, M., Zhang, L., Liang, Y., Yang, W., Wu, L., Cao, L., Feng, Y., Meng, Z., Chen, R., He, Y., Li, L., Feng, W., Lin, B., Xu, A., Jiang, M., Xie, Z., Zhang, G., Bian, K., …, & Gao, X. (2026). Efficacy and safety of pumecitinib 3% gel in treating mild-to-moderate atopic dermatitis: a multicentre randomized double-blind parallel placebo-controlled phase IIb clinical trial. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf363
Vancouver
Zhang L, Wang M, Zhang L, Liang Y, Yang W, Wu L, et al. Efficacy and safety of pumecitinib 3% gel in treating mild-to-moderate atopic dermatitis: a multicentre randomized double-blind parallel placebo-controlled phase IIb clinical trial. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljaf363
BibTeX
@article{Zhang2026,
author = {Zhang, Li and Wang, Mingyue and Zhang, Litao and Liang, Yunsheng and Yang, Wenlin and Wu, Liming and Cao, Lei and Feng, Yanyan and Meng, Zudong and Chen, Rixin and He, Yingxia and Li, Linfeng and Feng, Wenli and Lin, Bingjiang and Xu, Aie and Jiang, Meiying and Xie, Zhihong and Zhang, Guoqiang and Bian, Kunpeng and Ji, Chao and Yao, Weifeng and Pei, Xiaoping and Du, Daniel Y and Gao, Xinghua},
title = {Efficacy and safety of pumecitinib 3% gel in treating mild-to-moderate atopic dermatitis: a multicentre randomized double-blind parallel placebo-controlled phase IIb clinical trial},
journal = {British Journal of Dermatology},
year = {2026},
doi = {10.1093/bjd/ljaf363}
}
EUVIMED